-
1Academic Journal
Source: Modern Rheumatology Journal; Том 7, № 1 (2013); 66-72 ; Современная ревматология; Том 7, № 1 (2013); 66-72 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2013-1
Subject Terms: биологическая терапия, glucocorticosteroids, prednisone, prednisolone, methyl-prednisolone, deflazacort, methotrexate, azathioprine, nonsteroidal anti-inflammatory drugs, biological therapy, глюкокортикоиды, преднизон, преднизолон, метилпреднизолон, дефлазакорт, метотрексат, азатиоприн, нестероидные противовоспалительные препараты
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/469/447; Salvarani C., Cantini F., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372(9634):234-45. Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347(4):261—71. Бунчук Н.В. Ревматическая полимиалгия. В кн.: Н.В. Бунчук. Ревматические заболевания пожилых. М.: МЕДпресс-информ, 2010;87—135. Meliconi R., Pulsatelli L., Uguccioni M. et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica: quantitative analysis and influence of corticosteroid treatment. Arthr Rheum 1996;39:1199-207. Salvarani C., Cantini F., Olivieri I. et al. Proximal bursitis in active polymyalgia rheumatica. Ann Int Med 1997;127:27-31. Cantini F., Salvarani C., Olivieri I. et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheum 2001;28:1049-55. Cantini F., Niccoli L., Nannini C. et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheum 2005;23:462-8. Salvarani C., Barozzi L., Cantini F. et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008;67:758-61. Gonzalez-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheum 1998;25:1750-5. Gonzalez-Gay M.A. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthr Rheum 2004;33:289-93. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J. et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Baltimore: Medicine, 2005;84:269-76. Maradit-Kremers H., Nicola P.J., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthr Rheum 2005;52:722-32. Warrington K.J., Jarpa E.P., Crowson C.S. et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthr Res Ther 2009;11(2):R50. Barber H.S. Myalgic syndrome with constitutional effect: polymyalgia rheumatic. Ann Rheum Dis 1957;16:207-37. Healey L.A. Long-term follow-up of polymyalgia rheumatica: evidence of synovitis. Semin Arthr Rheum 1984;13:322-8. Bird H.A., Esselinckx W., Dixon A.S. et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38(5):434-9. Jones J.G., Hazleman B.L. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981;40(1):1-5. Chuang T.Y., Hunder G.G., Ilstrup D.M., Kurland L.T. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Bird H.A., Leeb B.F., Montecucco C.M. et al. European collaborating PMR group. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 2005;64:626-9. Hart F.D. Polymyalgia rheumatica. Br Med J 1969;2(5649):99-100. Hernandez-Rodriguez J., Font C., Garcia-Martinez A. et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients. Baltimore: Medicine, 2007;86(4):233-41. Angeli A., Guglielmi G., Dovio A. et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a crosssectional outpatient study. Bone 2006;39(2):253-9. Hernandez-Rodriguez J., Cid M.C., Lopez-Soto A. et al, Treatment of Polymyalgia Rheumatica. A SystematicReview. Arch Int Med 2009;169(20):1839-50. Caporali R., Cimmino M.A., Ferraccioli G. et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2004;141(7):493-500. Salvarani C., Macchioni P., Manzini C. et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Int Med 2007;146(9):631-9. Gonzalez-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M. et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheum 1999;26(6):1326-32. Narvaez J., Nolla-Sole J.M., Clavaguera M.T. et al. Long-term therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheum 1999;26(9):1945-52. Kremers H.M., Reinalda M.S., Crowson C.S. et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheum 2005;32(1):65—73. Fauchald P., Rygvold O., Oystese B. Temporal arteritis and polymyalgia rheumatica: clinical and biopsy findings. Ann Int Med 1972;77(6):845-52. Gabriel S.E., Sunku J., Salvarani C. et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthr Rheum 1997;40(10):1873-8. Spiera H., Davison S. Long-term follow-up of polymyalgia rheumatica. Mt Sinai J Med 1978;45(2):225-9. Hutchings A., Hollywood J., Lamping D.L. et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthr Rheum 2007;57(5):803-9. Cimmino M.A., Parodi M., Caporali R., Montecucco C. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann NY Acad Sci 2006;1069:315-21. Mowat A.G., Camp A.V. Polymyalgia rheumatica. J Bone Joint Surg Br 1971;53(4):701-10. Delecoeuillerie G., Joly P., Cohen de Lara A., Paolaggi J.B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;47(9):733-9. Ayoub W.T., Franklin C.M., Torretti D. Polymyalgia rheumatica: duration of therapy and long-term outcome. Am J Med 1985;79(3):309-15. Weyand C.M., Fulbright J.W., Evans J.M. et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Int Med 1999;159(6):577-84. Behn A.R., Perera T., Myles A.B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42(4):374-8. Myklebust G., Gran J.T. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis: a prospective two-year study in 273 patients. Scand J Rheum 2001;30(5):260-7. Cimmino M.A., Moggiana G., Montecucco C. et al. Long-term treatment of polymyalgia rheumatic with deflazacort. Ann Rheum Dis 1994;53(5):331—3. Lund B., Egsmose C., Jorgensen S., Krogsgaard M.R. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int 1987;41(6):316—20. Di Munno O., Imbimbo B., Mazzantini M. et al. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheum1995;22(8):1492-8. Krogsgaard M.R., Lund B., Johnsson B. A long-term prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheum 1995;22(9):1660-2. Dasgupta B., Dolan A.L., Panayi G.S., Fernandes L. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheum 1998;37(2):189—95. Salvarani C., Cantini F., Olivieri I. et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheum 2000;27(6):1470-6. Vander Veen M.J., Dinant H.J., van Booma-Frankfort C. et al. Can methotrexate be used as a steroid-sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55(4):218-23. Caporali R., Cimmino M.A., Ferraccioli G. et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2004;141(7):493-500. Ferraccioli G., Salaffi F., De Vita S. et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheum 1996;23(4):624-8. Cimmino M.A., Salvarani C., Macchioni P. et al, Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Longterm follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheum 2008;26(3):395-400. Feinberg H.L., Sherman J.D., Schrepferman C.G. et al. The use of methotrexate in polymyalgia rheumatica. J Rheum 1996;23(9):1550-2. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45(2):136-8. Salvarani C., Macchioni P., Manzini C. et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Int Med 2007;146(9):631-9. Mowat A.G., Camp A.V. Polymyalgia rheumatica. J Bone Joint Surg Br 1971;53(4):701-10. Littman B.H., Bjarnason D., Bryant G. et al. Steroid-sparing activity of tenidap in patients with polymyalgia rheumatica: a multicenter double-blind randomized placebo-controlled study. J Rheum 1995;22(6):1097-103. Kyle V., Hazleman B.L. Treatment of polymyalgia rheumatica and giant cell arteritis I: steroid regimens in the first two months. Ann Rheum Dis 1989;48(8):658—61. Kyle V., Hazleman B.L. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52(12):847-50. Wegrzyn J., Adeleine P., Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63(10):1232-4. Braun J., Kastner P., Flaxenberg P. et al. MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthr Rheum 2008;58(1):73-81. Kreiner F., Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthr Res Ther 2010;12(5):R176. Braunert L., Bruegel M., Pfrepper C. et al. Rituximab in the treatment of acquired haemophilia A in a patient with polymyalgia rheumatica. Hеmostaseologie 2010;30 (Suppl 1):S40-3. Seitz M., Reichenbach S., Bonel H.M. et al. Rapid induction of remission in large-vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141: 13156. doi:10.4414/smw.2011.13156. Dasgupta B., Salvarani C., Schirmer M. et al. members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheum 2008;35(2):270-7.
-
2Academic Journal
Authors: Сатыбалдыев, Азамат
Subject Terms: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ГЛЮКОКОРТИКОИДЫ, ПРЕДНИЗОН, ПРЕДНИЗОЛОН, МЕТИЛПРЕДНИЗОЛОН, ДЕФЛАЗАКОРТ, МЕТОТРЕКСАТ, АЗАТИОПРИН, НЕСТЕРОИДНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ, БИОЛОГИЧЕСКАЯ ТЕРАПИЯ
File Description: text/html
-
3Academic Journal
Source: Современная ревматология.
Subject Terms: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ГЛЮКОКОРТИКОИДЫ, ПРЕДНИЗОН, ПРЕДНИЗОЛОН, МЕТИЛПРЕДНИЗОЛОН, ДЕФЛАЗАКОРТ, МЕТОТРЕКСАТ, АЗАТИОПРИН, НЕСТЕРОИДНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ, БИОЛОГИЧЕСКАЯ ТЕРАПИЯ, 3. Good health
File Description: text/html
